Simon Zhornitsky

Dr. Simon Zhornitsky

Psychology, Southern Connecticut State University, New Haven, Connecticut, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2012 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Simon ZhornitskySimon Zhornitsky
Simon Zhornitsky
SPStéphane Potvin
Stéphane Potvin
Cannabidiol (CBD), a major phytocannabinoid constituent of cannabis, is attracting growing attention in medicine for its anxiolytic, antipsychotic, antiemetic and anti-inflammatory properties. However, up to this point, a comprehensive literature review of the effects of CBD in humans is lacking. The aim of the present systematic review is to examine the randomized and crossover studies that administered CBD to healthy controls and to clinical patients. A systematic search was performed in the electronic databases PubMed and EMBASE using the key word “cannabidiol”. Both monotherapy and combination studies (e.g., CBD + ∆9-THC) were included. A total of 34 studies were identified: 16 of these were experimental studies, conducted in healthy subjects, and 18 were conducted in clinical populations, including multiple sclerosis (six studies), schizophrenia and bipolar mania (four studies), social anxiety disorder (two studies), neuropathic and cancer pain (two studies), cancer anorexia (one study), Huntington’s disease (one study), insomnia (one study), and epilepsy (one study). Experimental studies indicate that a high-dose of inhaled/intravenous CBD is required to inhibit the effects of a lower dose of ∆9-THC. Moreover, some experimental and clinical studies suggest that oral/oromucosal CBD may prolong and/or intensify ∆9-THC-induced effects, whereas others suggest that it may inhibit ∆9-THC-induced effects. Finally, preliminary clinical trials suggest that high-dose oral CBD (150–600 mg/d) may exert a therapeutic effect for social anxiety disorder, insomnia and epilepsy, but also that it may cause mental sedation. Potential pharmacokinetic and pharmacodynamic explanations for these results are discussed.

1 January 2016 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
Simon ZhornitskySimon Zhornitsky
Simon Zhornitsky
KMKyla A. McKay
Kyla A. McKay
LMLuanne M. Metz
Luanne M. Metz
CTCharlotte E. Teunissen
Charlotte E. Teunissen
MRManu Rangachari
Manu Rangachari

16 November 2019 in NeuroImage
Verified
Journal Article
Open access
IDIsha Dhingra
Isha Dhingra
SZSheng Zhang
Sheng Zhang
Simon ZhornitskySimon Zhornitsky
Simon Zhornitsky
TLThang M. Le
Thang M. Le
WWWuyi Wang
Wuyi Wang
CLChiang-Shan R Li
Chiang-Shan R Li
Previous studies have suggested age-related differences in reward-directed behavior and cerebral processes in support of the age effects. However, it remains unclear how age may influence the processing of reward magnitude. Here, with 54 volunteers (22-74 years of age) participating in the Monetary Incentive Delay Task (MIDT) with explicit cues ($1, ¢1, or nil) and timed response to win, we characterized brain activations during anticipation and feedback and the effects of age on these regional activations. Behaviorally, age was associated with less reaction time (RT) difference between dollar and cent trials, as a result of slower response to the dollar trials; i.e., age was positively correlated with RT dollar - RT cent, with RT nil as a covariate. Both age and the RT difference ($1 - ¢1) were correlated with diminished activation of the right caudate head, right anterior insula, supplementary motor area (SMA)/pre-SMA, visual cortex, parahippocampal gyrus, right superior/middle frontal gyri, and left primary motor cortex during anticipation of $1 vs. ¢1 reward. Further, these regional activities mediated the age effects on RT differences. In responses to outcomes, age was associated with decreases in regional activations to dollar vs. cent loss but only because of higher age-related responses to cent losses. Together, these findings suggest age-related differences in sensitivity to the magnitude of reward. With lower cerebral responses during anticipation to win large rewards and higher responses to outcomes of small loss, aging incurs a constricted sensitivity to the magnitude of reward.

22 May 2014 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
MKMarcus W Koch
Marcus W Koch
Scott B PattenScott B Patten
Scott B Patten
SBSandy Berzins
Sandy Berzins
Simon ZhornitskySimon Zhornitsky
Simon Zhornitsky
JGJamie Greenfield
Jamie Greenfield
LMLuanne M Metz
Luanne M Metz
Background: Depression is a common comorbidity in multiple sclerosis (MS), but little is known about its long-term prognosis. Depression in the general population is usually episodic with relatively short-lasting depressive episodes. In this study we investigate the long-term prognosis of depression in MS. Methods: Using data from a large longitudinal observational study and from the Calgary MS clinic database, we investigated changes in Center for Epidemiological Studies Depression Scale (CESD) scores in MS patients over four years of follow-up. We used logistic regression to investigate the association of the factors sex, age, disease duration, Expanded Disability Status Scale (EDSS), depression at baseline, and antidepressant use with depression at each year of follow-up. Results: CESD scores remained largely stable, or decreased slightly over four years of follow-up, whereas EDSS scores steadily increased. Depression at baseline was the strongest predictor of depression at follow-up; the other factors were not or not consistently associated with depression at follow-up. As expected, antidepressant use was associated with a greater risk of depression at follow-up. Starting and stopping antidepressant treatment during follow-up was not associated with the risk of depression at follow-up or with significant change in CESD scores. Conclusion: In contrast to depression in the general population, depression in MS is largely chronic, which suggests a different pathophysiology.

29 April 2021 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
Thang M. LeThang M. Le
Thang M. Le
SPStéphane Potvin
Stéphane Potvin
Simon ZhornitskySimon Zhornitsky
Simon Zhornitsky
CLChiang-Shan R. Li
Chiang-Shan R. Li

15 February 2012 in Schizophrenia Research and Treatment
Verified
Journal Article
Open access
PDF file
Simon ZhornitskySimon Zhornitsky
Simon Zhornitsky
ESEmmanuel Stip
Emmanuel Stip
Long-acting injectable antipsychotics (LAIs) should offer better efficacy and tolerability, compared to oral antipsychotics due to improved adherence and more stable pharmacokinetics. However, data on LAIs has been mixed, with some studies finding that they are more effective and tolerable than oral antipsychotics, and others finding the contrary. One possibility for the disparate results may be that some studies administered different antipsychotics in the oral and injectable form. The present systematic review examined the efficacy and tolerability of LAIs versus their oral equivalents in randomized and naturalistic studies. In addition, it examined the impact of LAIs on special populations such as patients with first-episode psychosis, substance use disorders, and a history of violence or on involuntary outpatient commitment. Randomized studies suggest that not all LAIs are the same; for example, long-acting risperidone may be associated with equal or less side effects than oral risperidone, whereas fluphenazine decanoate and enanthate may be associated with equal or more side effects than oral fluphenazine. They also suggest that LAIs reduce risk of relapse versus oral antipsychotics in schizophrenia outpatients when combined with quality psychosocial interventions. For their part, naturalistic studies point to a larger magnitude of benefit for LAIs, relative to their oral equivalents particularly among first-episode patients.